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As of 2011, cancer was the leading cause 
of death in the United States, second only 
to heart disease. As cancer continues to 
become an ever-increasing threat to human 
health, the race is on to find an effective 
telomerase inhibitor. This inhibitor has 
to be functional enough to render the 
cancer cell unable to divide, while leaving 
the surrounding healthy cells relatively 
untouched. Research has established that 
the molecular structure of a compound 
known as BIBR 1532 has proven to be 
an effective telomerase inhibitor. Cancer 
is often referred to as being “immortal” 
because of its ability to divide an infinite 
amount of times. Normal cells are limited 
in the number of times they can divide by 
the caps on the ends of their chromosomes, 
called telomeres. These caps become 
degraded over time, signaling the cell to die 
when they become too short.  An enzyme 
known as telomerase lengthens the ends 
of telomeres in cancer cells, granting them 
immortality. Current research has shown 
that BIBR 1532 inhibits telomerase by 
preventing it from extending the copied 
strand any further than the length of the 
original strand of DNA. If telomerase is 
inhibited, the telomeres of cancer cells can 
no longer be elongated. Stripped of their 
immortality, the telomeres of cancer cells 
will become degraded and die. Research has 
not yet discovered what portion of BIBR 
1532 causes it to be such a good telomerase 
inhibitor. Research has shown that there are 
three substructures that must be present in 
order for it to act as a telomerase inhibitor: 
an aromatic ring containing a carboxylic 
acid and a conjugated amine group.  
During the summer of 2013, three novel 
compounds were made via synthesis of 
cinnamoyl chloride derivatives. These 
three compounds all contain active sites 
that are identical to those identified on 
BIBR 1532, with one key difference in 
the element attached to the aromatic 
ring. The compounds were purified and 
then tested against PC3 prostate cancer 
cell lines. Prostate, breast, and pancreatic 
cancers all have relatively high levels of 
telomerase activity, which is a primary 
reason why prostate cancer was chosen 
as a target cell line. The compounds were 
tested at three different concentrations: 
50uM, 75uM, 100uM. Drug assay 
were performed in order to determine 
at which concentration the compounds 
showed significant anti-cancer activity, 
while leaving behind enough cancer 
cells to harvest telomerase and test for 
telomerase inhibition. After performing 
the assays, it was determined that the 
ideal concentration of the compounds was 
75uM. All three compounds were shown 
to be more effective than BIBR 1532 at 
this concentration. The next step will be 
to test for telomerase inhibition using the 
TRAPeze assay. If these compounds prove 
to be telomerase inhibitors, it would be 
a breakthrough as to how BIBR 1532 
functions and could potentially lead to a 
more effective cancer treatment. While the 
compounds were tested using metastatic 
prostate cancer cells, these potential 
treatments have applications in both breast 
and pancreatic cancers as well.
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